| Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and … JD England, GS Gronseth, G Franklin, RG Miller, AK Asbury, GT Carter, ... Neurology 64 (2), 199-207, 2005 | 856 | 2005 |
| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 684 | 2017 |
| Spinal cord infarction: etiology and outcome WP Cheshire, CC Santos, EW Massey, JF Howard Jr Neurology 47 (2), 321-330, 1996 | 560 | 1996 |
| Practice Parameter: The Evaluation of Distal Symmetric Polyneuropathy: The Role of Autonomic Testing, Nerve Biopsy, and Skin Biopsy (An Evidence‐Based Review) Report of the … JD England, GS Gronseth, G Franklin, GT Carter, LJ Kinsella, JA Cohen, ... PM&R 1 (1), 14-22, 2009 | 433 | 2009 |
| Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, ... The Lancet Neurology 20 (7), 526-536, 2021 | 425 | 2021 |
| Practice Parameter: The Evaluation of Distal Symmetric Polyneuropathy: The Role of Laboratory and Genetic Testing (An Evidence‐Based Review) Report of the American Academy of … JD England, GS Gronseth, G Franklin, GT Carter, LJ Kinsella, JA Cohen, ... PM&R 1 (1), 5-13, 2009 | 370 | 2009 |
| A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis JF Howard Jr, RJ Barohn, GR Cutter, M Freimer, VC Juel, T Mozaffar, ... Muscle & nerve 48 (1), 76-84, 2013 | 247 | 2013 |
| Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review MK Hehir, LD Hobson-Webb, M Benatar, C Barnett, NJ Silvestri, ... Neurology 89 (10), 1069-1077, 2017 | 236 | 2017 |
| Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis JF Howard Jr, V Bril, TM Burns, R Mantegazza, M Bilinska, A Szczudlik, ... Neurology 92 (23), e2661-e2673, 2019 | 231 | 2019 |
| Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies JN Kornegay, JR Bogan, DJ Bogan, MK Childers, J Li, P Nghiem, ... Mammalian genome 23, 85-108, 2012 | 218 | 2012 |
| Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... Muscle & nerve 60 (1), 14-24, 2019 | 215 | 2019 |
| Myasthenia gravis: the role of complement at the neuromuscular junction JF Howard Jr Annals of the New York Academy of Sciences 1412 (1), 113-128, 2018 | 204 | 2018 |
| Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis PI Andrews, JM Massey, JF Howard Jr, DB Sanders Neurology 44 (7), 1208-1208, 1994 | 197 | 1994 |
| A genome-wide association study of myasthenia gravis AE Renton, HA Pliner, C Provenzano, A Evoli, R Ricciardi, MA Nalls, ... JAMA neurology 72 (4), 396-404, 2015 | 195 | 2015 |
| Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic S Jacob, S Muppidi, A Guidon, J Guptill, M Hehir, JF Howard, I Illa, ... Journal of the neurological sciences 412, 2020 | 190 | 2020 |
| Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs JN Kornegay, J Li, JR Bogan, DJ Bogan, C Chen, H Zheng, B Wang, ... Molecular Therapy 18 (8), 1501-1508, 2010 | 187 | 2010 |
| AAEE minimonograph# 25: single‐fiber electromyography in myasthenia gravis DB Sanders, JF Howard JR Muscle & Nerve: Official Journal of the American Association of …, 1986 | 184 | 1986 |
| Single‐fiber electromyography in myasthenia gravis DB Sanders, JF Howard Jr, TR Johns Neurology 29 (1), 68-68, 1979 | 165 | 1979 |
| Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 … JF Howard, RJ Nowak, GI Wolfe, ML Freimer, TH Vu, JL Hinton, ... JAMA neurology 77 (5), 582-592, 2020 | 159 | 2020 |
| Terminal complement inhibitor ravulizumab in generalized myasthenia gravis T Vu, A Meisel, R Mantegazza, D Annane, M Katsuno, R Aguzzi, ... NEJM evidence 1 (5), EVIDoa2100066, 2022 | 136 | 2022 |
Andreas MeiselCharité BerlinΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα charite.de
